Hyperparathyroidism Clinical Trial
Official title:
Pilot Study to Detect and Assess the Effect of Vitamin D Replacement on Gland Size by 4DCT in Patients With Primary Hyperparathyroidism (PHPT)
Verified date | March 2019 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical research study is to learn how the standard practice of giving Vitamin D supplements to patients with a Vitamin D deficiency may affect the size of the parathyroid glands in patients with PHPT and a Vitamin D deficiency.
Status | Completed |
Enrollment | 22 |
Est. completion date | May 30, 2018 |
Est. primary completion date | May 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: 1. Be diagnosed with PHPT (inappropriate PTH level in the setting of a high or high-normal corrected serum calcium level equal to or greater than 10.0 mg/dL) 2. Be considered an appropriate surgical candidate 3. Be older than 21 years of age 4. Have a vitamin D (25-OHD) level less than or equal to 20ng/ml 5. Female participants of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG) within two weeks before signing consent Exclusion Criteria: 1. Have any other functional tumors if they have familial multiple endocrine neoplasia syndrome 1 or 2 (MEN 1 or MEN 2) 2. Have a corrected calcium level greater than 13mg/dL 3. Have a recent history of kidney stones 4. Have a recent history of pancreatitis 5. Have a recent history of cardiac arrhythmia (eg atrial fibrillation) 6. Unable to keep still for 2 minutes without coughing 7. Having a body habitus that prevents adequate images to be obtained through the region of the parathyroids (ie typically weighing in excess of 250Lbs) 8. Have a serum creatinine greater than 2.0 mg/dl 9. Have hypersensitivity to ergocalciferol or any component of the formulation |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Size of parathyroid glands | Size of individual gland recorded while only the gland with maximum size at baseline included for analysis of primary endpoint. With sample size of 22, a two-sided 95% confidence interval for mean changes in size of parathyroid glands will extend 2.09 from observed mean, assuming that standard deviation is known to be 5 and confidence interval is based on the z statistic. Parameters for parathyroid glands compared pre- and post-replacement on an individual, gland-by-gland basis. | Baseline to 3-months post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00377312 -
7 Day Continuous Parathyroid Hormone IV Infusion
|
Phase 0 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT04040946 -
Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention
|
Phase 3 | |
Recruiting |
NCT03053999 -
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
|
||
Withdrawn |
NCT02711059 -
Insulin Resistance in Primary Hyperparathyroidism
|
N/A | |
Completed |
NCT01691781 -
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
|
N/A | |
Completed |
NCT00887666 -
Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure
|
N/A | |
Terminated |
NCT03044600 -
Gene Expression in Hyperparathyroidism
|
||
Completed |
NCT03747029 -
Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
|
||
Completed |
NCT01872429 -
Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients
|
N/A | |
Completed |
NCT00800358 -
Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism
|
N/A | |
Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
Completed |
NCT03968510 -
Swalqol in Primary Hyperparathyroidism
|
||
Completed |
NCT00501215 -
Effect of Parathyroidectomy on Sleep
|
N/A | |
Completed |
NCT02591160 -
Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism
|
N/A | |
Recruiting |
NCT05299632 -
F-18 PSMA for Localization of Parathyroid Adenoma
|
||
Recruiting |
NCT02986607 -
Corticosteroid Rhythms in Hypoparathyroid Patients
|
Early Phase 1 | |
Completed |
NCT02432599 -
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas
|
Phase 2 | |
Completed |
NCT02524041 -
Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism
|
N/A | |
Recruiting |
NCT05667090 -
Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients
|
N/A |